Wave Life Sciences
Wave Life Sciences' revenue fell 60.5% to $43 million in fiscal 2025. Its operating margin was −504.1%, down from −101.9% a year earlier. Free cash flow was −$188 million. The diluted share count rose 22.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Wave Life Sciences does
Wave Life Sciences is a clinical-stage biotechnology company with no approved products. It develops RNA medicines, which are drugs built from short pieces of genetic material that either silence a faulty gene's message or correct it. Its platform, called PRISM, uses chemistry changes it designed to make these molecules last longer and reach the right tissues without complex delivery carriers such as lipid nanoparticles or viruses.
Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and a genetic liver disease (WVE-008). It also has clinical programs for Duchenne muscular dystrophy and Huntington's disease, and several earlier programs. Its tools include RNA interference and RNA editing, which uses enzymes already inside cells.
Wave earns no product revenue. It funds its work by raising money and through collaborations with partners, which can pay it when programs reach milestones. It is incorporated in Singapore. It competes with other drug developers in each disease area it targets.
Its biggest risks, as it describes them
- It has a history of losses, expects more, and needs substantial additional funding.
- Its approach to RNA medicines is new and may never lead to a product that can be sold.
- Its trials can be delayed by slow patient enrollment or fail to meet regulators' standards.
- It relies on collaboration partners and on outside companies to run studies and trials.
- It may not obtain or protect patent rights or secure marketing approval for its drug candidates.
Income statement
Wave Life Sciences lost money in fiscal 2025: a net loss of $204 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 151 | 88 | 200 | 302 | 602 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 2.5x | 1.4x | 1.3x | 2.9x | 6.5x |
| Quick ratio | 2.5x | 1.4x | 1.3x | 2.9x | 6.5x |
Cash flow
Projections
Project Wave Life Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Wave Life Sciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 2,987.0% | −144.7% | −501.0% |
| Altman Z'' | −12.46 | −6.96 | 1.15 |
| Accruals ratio | −18.1% | 17.2% | −3.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Wave Life Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Wave Life Sciences | FY25 | −60.5% | −504.1% | −440.5% | — | — | — | |
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | Compare |
| Protagonist Therapeutics | FY25 | −89.4% | −343.6% | 121.9% | — | — | — | Compare |
| Septerna | FY25 | 4,174.5% | −148.6% | 238.7% | — | — | — | Compare |
| Kymera Therapeutics | FY25 | −16.7% | −891.1% | −597.6% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 4 | 14 | 16 | 20 | 41 | 4 | 113 | 108 | 43 |
| Revenue growth | 877.0% | 149.4% | 289.1% | 10.9% | 25.6% | 104.0% | −91.1% | 3,005.1% | −4.4% | −60.5% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 41 | 79 | 134 | 175 | 131 | 122 | 116 | 130 | 160 | 183 |
| Operating income | −56 | −102 | −160 | −208 | −153 | −127 | −163 | −68 | −110 | −215 |
| Net income | −56 | −102 | −147 | −194 | −150 | −122 | −162 | −58 | −97 | −204 |
| Diluted EPS (US$) | −2.44 | −3.85 | −5.06 | −5.72 | −3.82 | −2.36 | −2.05 | −0.54 | −0.70 | −1.21 |
| Diluted shares (millions) | 23 | 26 | 29 | 34 | 39 | 52 | 79 | 106 | 138 | 169 |
| Cash flow | ||||||||||
| Cash from operations | −32 | −84 | −23 | −188 | −116 | −89 | −128 | −19 | −151 | −188 |
| Capital expenditure | 6 | 19 | 10 | 4 | 1 | 1 | 1 | 1 | 1 | 1 |
| Free cash flow | −37 | −103 | −33 | −192 | −117 | −90 | −129 | −21 | −152 | −188 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 12 | 16 | 20 | 14 | 16 | 17 | 10 | 13 | 25 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 150 | 142 | 175 | 147 | 184 | 151 | 88 | 200 | 302 | 602 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 165 | 182 | 296 | 284 | 279 | 207 | 146 | 275 | 352 | 638 |
| Total liabilities | 22 | 34 | 215 | 213 | 189 | 167 | 184 | 227 | 135 | 112 |
| Shareholders' equity | 135 | 140 | 73 | 64 | 83 | 32 | −45 | 40 | 210 | 518 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −3,752.2% | −2,764.3% | −1,106.7% | −1,303.4% | −763.9% | −310.1% | −4,459.3% | −60.0% | −101.9% | −504.1% |
| Net margin | −3,748.2% | −2,753.2% | −1,017.4% | −1,211.5% | −746.7% | −298.4% | −4,434.7% | −50.8% | −89.6% | −478.3% |
| Free cash flow margin | −2,524.7% | −2,768.8% | −227.6% | −1,202.2% | −584.4% | −218.6% | −3,539.1% | −18.1% | −140.3% | −440.5% |
| Rule of 40 (growth + FCF margin) | −1,647.7% | −2,619.4% | 61.6% | −1,191.3% | −558.7% | −114.6% | −3,630.2% | 2,987.0% | −144.7% | −501.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −38.6% | −74.4% | −137.7% | −282.5% | −204.6% | −212.1% | — | — | −77.9% | −56.2% |
| Return on assets | −33.7% | −58.8% | −61.4% | −66.8% | −53.2% | −50.3% | −91.6% | −27.3% | −30.9% | −41.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |